Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by PoorOpinionon Oct 03, 2018 4:12pm

129 Views

Post# 28740305

RE:RE:insiders

youngpupper wrote:

cashcrab wrote: last purchase was Macnee (vice chairman of Mastercard)

An insider drops 50K at 0.34 and retailers believe their winning selling at 0.36 lmao this why people get FOMO on penny stocks.

its violent mood swings from FOMO to fear of being the bag-holder that really gets me.

Truth is this stock doesnt require a ongoing daily commentary, too little happens to justify one, so there is a whole lot of hot air filling up the spaces inbetween.

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale